Data gathered: November 27
AI Stock Analysis - Castle Biosciences (CSTL)
Analysis generated October 25, 2024. Powered by Chat GPT.
Castle Biosciences, Inc. (NASDAQ: CSTL) is a notable player in the personalized cancer diagnostics sector. The company focuses on developing and commercializing diagnostic and prognostic tests for cancers, which provide clinicians with individualized treatment information, aiding them in making more informed decisions. Castle Biosciences aims to revolutionize the treatment landscape by ensuring that patients receive the most effective therapies tailored to their specific conditions.
Stock Alerts - Castle Biosciences (CSTL)
 |
Castle Biosciences | November 26 Price is up by 5% in the last 24h. |
|
Castle Biosciences | November 20 Insider Alert: Stokes Frank is selling shares |
|
Castle Biosciences | November 15 Price is down by -5.2% in the last 24h. |
|
Castle Biosciences | November 15 Insider Alert: MAETZOLD DEREK J is selling shares |
Alternative Data for Castle Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 33,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 22 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 33 | Sign up | Sign up | Sign up |
| Facebook Followers | 689 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,002 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 987 | Sign up | Sign up | Sign up |
| Twitter Followers | 753 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 445 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 76 | Sign up | Sign up | Sign up |
| Linkedin Employees | 557 | Sign up | Sign up | Sign up |
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions.
| Price | $30.44 |
| Target Price | Sign up |
| Volume | 86,220 |
| Market Cap | $835M |
| Year Range | $17.4 - $34.67 |
| Dividend Yield | 0% |
| PE Ratio | 140.52 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
First Horizon Advisors Inc. Cuts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)November 25 - ETF Daily News |
|
Connor Clark & Lunn Investment Management Ltd. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL)November 24 - ETF Daily News |
 |
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 19 - Yahoo |
 |
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive YearNovember 18 - Yahoo |
|
Castle Biosciences (NASDAQ:CSTL) Shares Down 7.3% on Insider SellingNovember 15 - ETF Daily News |
|
Brokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $37.88November 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 86M | 16M | 70M | 2.3M | 11M | 0.080 |
| Q2 '24 | 87M | 15M | 72M | 8.9M | 10M | 0.310 |
| Q1 '24 | 73M | 14M | 59M | -2.5M | -230,000 | -0.090 |
| Q4 '23 | 66M | 12M | 54M | -2.6M | -130,000 | -0.100 |
| Q3 '23 | 61M | 11M | 50M | -6.9M | -4.6M | -0.260 |
Insider Transactions View All
| Stokes Frank filed to sell 30,823 shares at $30.4. November 19 '24 |
| Stokes Frank filed to sell 31,623 shares at $29.9. November 19 '24 |
| MAETZOLD DEREK J filed to sell 6,151 shares at $34.2. November 14 '24 |
| MAETZOLD DEREK J filed to sell 6,160 shares at $34.2. November 14 '24 |
| MAETZOLD DEREK J filed to sell 63,891 shares at $34.2. November 14 '24 |
Similar companies
Read more about Castle Biosciences (CSTL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Castle Biosciences?
The Market Cap of Castle Biosciences is $835M.
What is Castle Biosciences' PE Ratio?
As of today, Castle Biosciences' PE (Price to Earnings) ratio is 140.52.
What is the current stock price of Castle Biosciences?
Currently, the price of one share of Castle Biosciences stock is $30.44.
How can I analyze the CSTL stock price chart for investment decisions?
The CSTL stock price chart above provides a comprehensive visual representation of Castle Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Castle Biosciences shares. Our platform offers an up-to-date CSTL stock price chart, along with technical data analysis and alternative data insights.
Does CSTL offer dividends to its shareholders?
As of our latest update, Castle Biosciences (CSTL) does not offer dividends to its shareholders. Investors interested in Castle Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Castle Biosciences?
Some of the similar stocks of Castle Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.